Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation

Minou P. Tran, Jennifer Lynn Larsen, William C. Duckworth, Elizabeth I. Ruby, Suzanne A. Miller, Kecia Frisbie, Rodney J. Taylor, Robert J. Stratta

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE - Hypoglycemic symptoms have been reported by more than half of pancreas transplantation (PTX) recipients. To better understand the mechanism for the hypoglycemia documented in some of these patients, we studied the glucose and pancreatic hormone response to Sustacal in patients with and without hypoglycemia following PTX. RESEARCH DESIGN AND METHODS - Twelve patients with established, repeated episodes of hypoglycemia following PTX (hypo) were case-matched to PTX recipients without hypoglycemic symptoms (control; n = 7). On the day of the study, fasting glucose, free and total immunoreactive insulin (IRI), C-peptide, proinsulin, and glucagon were drawn (time O); Sustacal was administered; and glucose, free and total IRI, and C- peptide were assayed at 15, 30, 45, 75, 120, 150, 180, and 240 min. Based on the glucose response to Sustacal, the hypo group was further divided into those whose glucose rose after Sustacal (hypo-high; n = 7) and those with no increase in glucose from baseline concentration (hypo-flat; n = 5). RESULTS - Before the administration of Sustacal, the hypo-high group had a lower fasting free/total IRI (0.26 ± 0.06, mean ± SE) than the hypo-flat (0.51 ± 0.02) or control (0.52 ± 0.04) groups (both P < 0.05 compared with hypo- high). The glucose response to Sustacal was greatest in the hypo-high group as defined. Area under the curve (AUC) for total IRI following Sustacal was also greatest in the hypo-high group (P < 0.05 compared with both control and hypo-flat groups), but there was no significant difference in free IRI AUC following Sustacal between the three groups. Two individuals developed hypoglycemia during the Sustacal challenge, both in the hypo-high group. CONCLUSIONS - The lower fasting free/total IRI ratio and greater increase in glucose and total IRI in response to Sustacal in the hypo-high group compared with either the hypo-flat or control groups are consistent with the presence of significant quantities of anti-insulin antibodies in the hypo-high group. Because anti-insulin antibodies are, in turn, an established cause of episodic hypoglycemia, this study provides the first data to support the hypothesis that significant quantities of anti-insulin antibodies are a cause of symptomatic hypoglycemia following PTX in some recipients.

Original languageEnglish (US)
Pages (from-to)988-993
Number of pages6
JournalDiabetes Care
Volume17
Issue number9
DOIs
StatePublished - Sep 1994

Fingerprint

Insulin Antibodies
Pancreas Transplantation
Hypoglycemia
Anti-Idiotypic Antibodies
Glucose
Insulin
Fasting
C-Peptide
Hypoglycemic Agents
Area Under Curve
Pancreatic Hormones
Glucagon
Research Design
Control Groups

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Tran, M. P., Larsen, J. L., Duckworth, W. C., Ruby, E. I., Miller, S. A., Frisbie, K., ... Stratta, R. J. (1994). Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation. Diabetes Care, 17(9), 988-993. https://doi.org/10.2337/diacare.17.9.988

Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation. / Tran, Minou P.; Larsen, Jennifer Lynn; Duckworth, William C.; Ruby, Elizabeth I.; Miller, Suzanne A.; Frisbie, Kecia; Taylor, Rodney J.; Stratta, Robert J.

In: Diabetes Care, Vol. 17, No. 9, 09.1994, p. 988-993.

Research output: Contribution to journalArticle

Tran, MP, Larsen, JL, Duckworth, WC, Ruby, EI, Miller, SA, Frisbie, K, Taylor, RJ & Stratta, RJ 1994, 'Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation', Diabetes Care, vol. 17, no. 9, pp. 988-993. https://doi.org/10.2337/diacare.17.9.988
Tran, Minou P. ; Larsen, Jennifer Lynn ; Duckworth, William C. ; Ruby, Elizabeth I. ; Miller, Suzanne A. ; Frisbie, Kecia ; Taylor, Rodney J. ; Stratta, Robert J. / Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation. In: Diabetes Care. 1994 ; Vol. 17, No. 9. pp. 988-993.
@article{e36f37b31995414e86a671db5fd5758f,
title = "Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation",
abstract = "OBJECTIVE - Hypoglycemic symptoms have been reported by more than half of pancreas transplantation (PTX) recipients. To better understand the mechanism for the hypoglycemia documented in some of these patients, we studied the glucose and pancreatic hormone response to Sustacal in patients with and without hypoglycemia following PTX. RESEARCH DESIGN AND METHODS - Twelve patients with established, repeated episodes of hypoglycemia following PTX (hypo) were case-matched to PTX recipients without hypoglycemic symptoms (control; n = 7). On the day of the study, fasting glucose, free and total immunoreactive insulin (IRI), C-peptide, proinsulin, and glucagon were drawn (time O); Sustacal was administered; and glucose, free and total IRI, and C- peptide were assayed at 15, 30, 45, 75, 120, 150, 180, and 240 min. Based on the glucose response to Sustacal, the hypo group was further divided into those whose glucose rose after Sustacal (hypo-high; n = 7) and those with no increase in glucose from baseline concentration (hypo-flat; n = 5). RESULTS - Before the administration of Sustacal, the hypo-high group had a lower fasting free/total IRI (0.26 ± 0.06, mean ± SE) than the hypo-flat (0.51 ± 0.02) or control (0.52 ± 0.04) groups (both P < 0.05 compared with hypo- high). The glucose response to Sustacal was greatest in the hypo-high group as defined. Area under the curve (AUC) for total IRI following Sustacal was also greatest in the hypo-high group (P < 0.05 compared with both control and hypo-flat groups), but there was no significant difference in free IRI AUC following Sustacal between the three groups. Two individuals developed hypoglycemia during the Sustacal challenge, both in the hypo-high group. CONCLUSIONS - The lower fasting free/total IRI ratio and greater increase in glucose and total IRI in response to Sustacal in the hypo-high group compared with either the hypo-flat or control groups are consistent with the presence of significant quantities of anti-insulin antibodies in the hypo-high group. Because anti-insulin antibodies are, in turn, an established cause of episodic hypoglycemia, this study provides the first data to support the hypothesis that significant quantities of anti-insulin antibodies are a cause of symptomatic hypoglycemia following PTX in some recipients.",
author = "Tran, {Minou P.} and Larsen, {Jennifer Lynn} and Duckworth, {William C.} and Ruby, {Elizabeth I.} and Miller, {Suzanne A.} and Kecia Frisbie and Taylor, {Rodney J.} and Stratta, {Robert J.}",
year = "1994",
month = "9",
doi = "10.2337/diacare.17.9.988",
language = "English (US)",
volume = "17",
pages = "988--993",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation

AU - Tran, Minou P.

AU - Larsen, Jennifer Lynn

AU - Duckworth, William C.

AU - Ruby, Elizabeth I.

AU - Miller, Suzanne A.

AU - Frisbie, Kecia

AU - Taylor, Rodney J.

AU - Stratta, Robert J.

PY - 1994/9

Y1 - 1994/9

N2 - OBJECTIVE - Hypoglycemic symptoms have been reported by more than half of pancreas transplantation (PTX) recipients. To better understand the mechanism for the hypoglycemia documented in some of these patients, we studied the glucose and pancreatic hormone response to Sustacal in patients with and without hypoglycemia following PTX. RESEARCH DESIGN AND METHODS - Twelve patients with established, repeated episodes of hypoglycemia following PTX (hypo) were case-matched to PTX recipients without hypoglycemic symptoms (control; n = 7). On the day of the study, fasting glucose, free and total immunoreactive insulin (IRI), C-peptide, proinsulin, and glucagon were drawn (time O); Sustacal was administered; and glucose, free and total IRI, and C- peptide were assayed at 15, 30, 45, 75, 120, 150, 180, and 240 min. Based on the glucose response to Sustacal, the hypo group was further divided into those whose glucose rose after Sustacal (hypo-high; n = 7) and those with no increase in glucose from baseline concentration (hypo-flat; n = 5). RESULTS - Before the administration of Sustacal, the hypo-high group had a lower fasting free/total IRI (0.26 ± 0.06, mean ± SE) than the hypo-flat (0.51 ± 0.02) or control (0.52 ± 0.04) groups (both P < 0.05 compared with hypo- high). The glucose response to Sustacal was greatest in the hypo-high group as defined. Area under the curve (AUC) for total IRI following Sustacal was also greatest in the hypo-high group (P < 0.05 compared with both control and hypo-flat groups), but there was no significant difference in free IRI AUC following Sustacal between the three groups. Two individuals developed hypoglycemia during the Sustacal challenge, both in the hypo-high group. CONCLUSIONS - The lower fasting free/total IRI ratio and greater increase in glucose and total IRI in response to Sustacal in the hypo-high group compared with either the hypo-flat or control groups are consistent with the presence of significant quantities of anti-insulin antibodies in the hypo-high group. Because anti-insulin antibodies are, in turn, an established cause of episodic hypoglycemia, this study provides the first data to support the hypothesis that significant quantities of anti-insulin antibodies are a cause of symptomatic hypoglycemia following PTX in some recipients.

AB - OBJECTIVE - Hypoglycemic symptoms have been reported by more than half of pancreas transplantation (PTX) recipients. To better understand the mechanism for the hypoglycemia documented in some of these patients, we studied the glucose and pancreatic hormone response to Sustacal in patients with and without hypoglycemia following PTX. RESEARCH DESIGN AND METHODS - Twelve patients with established, repeated episodes of hypoglycemia following PTX (hypo) were case-matched to PTX recipients without hypoglycemic symptoms (control; n = 7). On the day of the study, fasting glucose, free and total immunoreactive insulin (IRI), C-peptide, proinsulin, and glucagon were drawn (time O); Sustacal was administered; and glucose, free and total IRI, and C- peptide were assayed at 15, 30, 45, 75, 120, 150, 180, and 240 min. Based on the glucose response to Sustacal, the hypo group was further divided into those whose glucose rose after Sustacal (hypo-high; n = 7) and those with no increase in glucose from baseline concentration (hypo-flat; n = 5). RESULTS - Before the administration of Sustacal, the hypo-high group had a lower fasting free/total IRI (0.26 ± 0.06, mean ± SE) than the hypo-flat (0.51 ± 0.02) or control (0.52 ± 0.04) groups (both P < 0.05 compared with hypo- high). The glucose response to Sustacal was greatest in the hypo-high group as defined. Area under the curve (AUC) for total IRI following Sustacal was also greatest in the hypo-high group (P < 0.05 compared with both control and hypo-flat groups), but there was no significant difference in free IRI AUC following Sustacal between the three groups. Two individuals developed hypoglycemia during the Sustacal challenge, both in the hypo-high group. CONCLUSIONS - The lower fasting free/total IRI ratio and greater increase in glucose and total IRI in response to Sustacal in the hypo-high group compared with either the hypo-flat or control groups are consistent with the presence of significant quantities of anti-insulin antibodies in the hypo-high group. Because anti-insulin antibodies are, in turn, an established cause of episodic hypoglycemia, this study provides the first data to support the hypothesis that significant quantities of anti-insulin antibodies are a cause of symptomatic hypoglycemia following PTX in some recipients.

UR - http://www.scopus.com/inward/record.url?scp=0027994605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027994605&partnerID=8YFLogxK

U2 - 10.2337/diacare.17.9.988

DO - 10.2337/diacare.17.9.988

M3 - Article

C2 - 7988320

AN - SCOPUS:0027994605

VL - 17

SP - 988

EP - 993

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -